Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03999515
Title Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients With Double Negative Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors University of Washington

prostate adenocarcinoma


Enzalutamide + Erdafitinib

Abiraterone + Erdafitinib

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.